Leqvio Cost in Missouri 2026: Prices, Insurance, Medicaid and Compounding Options

What Is Leqvio and Why Does Cost Matter in Missouri?

Leqvio (inclisiran) is a small interfering RNA (siRNA) drug that silences PCSK9 production in hepatocytes, lowering LDL cholesterol by roughly 50% with only two injections per year after the loading phase. Because it is administered in a clinical setting rather than self-injected at home, the billing pathway is different from most specialty drugs, and that pathway heavily shapes what Missouri patients actually pay.

The FDA approved Leqvio in December 2021 for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering on top of maximally tolerated statin therapy [1]. The key ORION-10 and ORION-11 trials (combined N = 3,457) showed inclisiran 284 mg reduced LDL-C by 49.9% to 52.3% versus placebo at 510 days, with a safety profile similar to placebo [2].

Missouri has roughly 1.2 million adults living with cardiovascular disease according to CDC estimates [3], and a meaningful portion of those patients may qualify for inclisiran. Understanding the real cost structure before booking an appointment can save thousands of dollars per year.

Leqvio List Price vs. Real Cash Price in Missouri 2026

The Novartis wholesale acquisition cost for Leqvio is approximately $3,240 per injection (or $540 per month averaged across the year). For a patient receiving two injections per year after the first year, the annual spend at list price approaches $6,480.

That number is not what most patients pay. Here is how the actual price breaks down across different payer scenarios in Missouri:

Cash-pay, no insurance: The retail cash price at Missouri pharmacies mirrors the list price closely, near $540/month equivalent. No large pharmacy benefit manager discounts apply to a buy-and-bill injectable in the same way they do for oral drugs. A patient without any insurance or assistance program would face the full cost.

Commercial insurance with prior authorization: Most large commercial plans (Blue Cross Blue Shield of Kansas City, Cigna, Aetna, United Healthcare) cover Leqvio under the medical benefit rather than the pharmacy benefit because it is administered in-office. After prior authorization confirming an ASCVD or HeFH diagnosis and documentation of statin intolerance or inadequate response, copays vary widely. Many commercially insured patients pay $0 to $100 per injection after using the Novartis savings card.

Medicare Part B: Inclisiran billed under Part B is covered with the standard 20% coinsurance after the Part B deductible ($257 in 2026). A Medigap plan covering Part B coinsurance would bring that to near $0. Without Medigap, 20% of $3,240 is approximately $648 per injection.

Medicare Part D: Leqvio does not typically flow through Part D because it is buy-and-bill, but some pharmacy dispensing arrangements exist. Patients in that pathway should confirm billing codes with their prescriber.

Missouri Medicaid Coverage for Leqvio: The Short Answer

Missouri Medicaid does not cover Leqvio for the ASCVD or familial hypercholesterolemia indications as of 2026. The only Medicaid-covered indication in Missouri's preferred drug list is a narrow type 2 diabetes carve-out that applies to very few patients seeking inclisiran for its primary cardiovascular lipid-lowering purpose.

This is a meaningful gap. Missouri expanded Medicaid under the Affordable Care Act through Amendment 2 (effective October 2021), adding roughly 275,000 beneficiaries [4]. A large fraction of those newly eligible adults carry cardiovascular risk factors. Without Medicaid coverage, those patients are left with compounded inclisiran, patient assistance programs, or alternative lipid-lowering agents as their primary options.

Patients whose physicians believe Leqvio is medically necessary can request a prior authorization exception to Missouri Medicaid's exclusion. Approval rates for such exceptions for non-covered specialty drugs are low, but documented statin intolerance combined with a high-risk cardiovascular history (recent ACS, multiple MIs) can support an appeal under the Missouri HealthNet appeals process.

The American College of Cardiology and American Heart Association's 2022 Guideline for the Management of Patients with Chronic Coronary Disease states: "For patients with very high-risk ASCVD and LDL-C levels 70 mg/dL or higher despite maximally tolerated statin therapy and ezetimibe, PCSK9 inhibitors are recommended (Class I, LOE: A)" [5]. That guideline language may support a Medicaid medical necessity appeal.

Commercial Insurance Coverage and Prior Authorization in Missouri

Most commercial plans operating in Missouri require prior authorization for Leqvio, and the criteria generally mirror the FDA label with a few additional hurdles.

Typical commercial PA requirements in Missouri include:

• Confirmed diagnosis of ASCVD (prior MI, stroke, or symptomatic PAD) or HeFH by genotype or clinical criteria
• Documentation of a maximally tolerated statin for at least 4 to 8 weeks
• LDL-C above 70 mg/dL (or above 100 mg/dL for some plans) despite statin therapy
• Consideration of ezetimibe before or alongside inclisiran for some plans

Once PA is granted, coverage typically runs for 12 months with annual renewal. The prescriber's office handles the PA paperwork in most cases, and Missouri telehealth practices can initiate the process remotely.

Blue Cross Blue Shield of Missouri (Anthem) covers inclisiran under its specialty tier for members with qualifying diagnoses, subject to the criteria above. UnitedHealthcare's Missouri formularies list Leqvio as a Tier 4 or Tier 5 specialty drug requiring prior authorization, with a specialty copay that the Novartis savings card may offset.

The Novartis Leqvio Savings Card: How It Works in Missouri

Novartis operates an out-of-pocket savings program for commercially insured patients. Eligible patients with commercial or private insurance pay a reduced amount per injection, with some patient reports of $0 copay after the card is applied.

Key restrictions: the savings card is not valid for patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government program. Missouri patients who are dual-eligible (Medicare and Medicaid) cannot use the card.

To use the savings card in Missouri:

1. Confirm the prescriber is enrolled with Novartis's buy-and-bill account or that the infusion center accepts the program.
2. Enroll at the Novartis patient services portal before the first injection date.
3. Bring the card details to the administering provider's billing department.
4. The savings apply at the point of service, reducing the patient's out-of-pocket portion after insurance processes the claim.

There is no income cap for the commercial savings card. The program is available to any commercially insured Missouri patient whose plan covers Leqvio, regardless of household income.

Compounded Inclisiran in Missouri: Is It Legal?

Compounded inclisiran is available in Missouri through licensed 503A compounding pharmacies, and prescribing it is legal under current state and federal rules as of early 2026. This is one of the most common questions Missouri patients ask, so the distinction between 503A and 503B designations matters here.

A 503A pharmacy compounds drugs for individual patients based on a valid prescription from a licensed prescriber. Missouri has a number of 503A-licensed compounding pharmacies that may prepare inclisiran formulations. The drug is not on the FDA's 503A bulk drug substances list, but compounders operating under physician-directed custom compounding have prepared siRNA-based formulations for individual patients where a clinical rationale exists.

A 503B outsourcing facility produces larger batches without individual prescriptions and faces stricter FDA oversight. Inclisiran does not appear on the current 503B formulary, which limits large-scale production but does not restrict the 503A individual-prescription pathway.

The cost of compounded inclisiran at a Missouri 503A pharmacy varies by formulation and supplier but is reported to be significantly lower than the Novartis list price, with some patients accessing it at near zero marginal cost when prescribed through a telehealth practice that works with a specific compounding pharmacy. Patients should verify that their compounding pharmacy holds a valid Missouri Board of Pharmacy license and that the prescribing physician has documented the clinical rationale in the medical record.

One critical caution: compounded drugs are not FDA-approved, and bioequivalence data for compounded inclisiran versus Leqvio is not established in published peer-reviewed literature. The clinical evidence base (ORION-10, ORION-11, and the broader ORION program) applies to the Novartis formulation specifically [2]. Patients and prescribers should weigh the cost savings against the absence of equivalent efficacy and safety data.

Telehealth Prescribing of Leqvio in Missouri

Missouri permits telehealth prescribing of Leqvio. A physician or advanced practice provider licensed in Missouri can evaluate a patient via synchronous audio-video telehealth, review lipid panels and cardiovascular history, and issue a prescription for inclisiran without an in-person visit for the initial consultation.

The administration itself still requires an in-person visit. Inclisiran is a subcutaneous injection given by a healthcare provider (physician's office, infusion center, or cardiology clinic), so the patient must appear physically for each injection appointment. Telehealth handles the consultation, lab review, prior authorization initiation, and follow-up; the injection visit is separate.

Missouri's telehealth parity law (Mo. Rev. Stat. Section 376.1900) requires commercial insurers to cover telehealth services at parity with in-person services for the same diagnosis code. That means the consultation cost for Leqvio management via telehealth should be reimbursed at the same rate as an office visit.

HealthRX operates telehealth services in Missouri and can connect patients with a licensed prescriber who will review their lipid panel, ASCVD risk, statin history, and insurance situation to determine whether Leqvio or compounded inclisiran is the right pathway.

PCSK9 Inhibitor Alternatives and Their Missouri Cost Comparison

Inclisiran is not the only PCSK9-pathway drug available in Missouri. Patients who face coverage barriers have two FDA-approved monoclonal antibody alternatives and one oral option.

Evolocumab (Repatha, Amgen): A self-injected monoclonal antibody dosed monthly or biweekly. List price is approximately $580/month. The FOURIER trial (N = 27,564) showed evolocumab reduced major adverse cardiovascular events by 15% versus placebo over a median 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [6]. Missouri Medicaid covers Repatha for ASCVD with prior authorization, making it a viable option when Leqvio's Medicaid exclusion is the barrier.

Alirocumab (Praluent, Sanofi/Regeneron): Also monthly self-injected, list price near $560/month. The ODYSSEY OUTCOMES trial (N = 18,924) showed alirocumab reduced major cardiovascular events after ACS (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) [7]. Missouri Medicaid covers Praluent for ASCVD with prior authorization.

Bempedoic acid (Nexletol, Esperion): An oral non-statin LDL-lowering agent. The CLEAR Outcomes trial (N = 13,970) showed bempedoic acid reduced major cardiovascular events by 13% in statin-intolerant patients (HR 0.87 to 95% CI 0.79 to 0.96, P = 0.004) [8]. Missouri Medicaid covers Nexletol. List price is roughly $280/month but generic versions are anticipated.

For Missouri Medicaid patients excluded from Leqvio coverage, evolocumab or alirocumab with a Medicaid prior authorization may provide equivalent LDL-C reduction at no cost to the patient.

Patient Assistance Program: Novartis Entresto/Leqvio Foundation

Novartis offers a patient assistance program (PAP) for uninsured or underinsured patients who do not qualify for the commercial savings card. The program provides Leqvio at no cost to patients who meet income and insurance eligibility criteria.

Eligibility generally requires:

• U.S. resident (Missouri qualifies)
• No coverage from any government insurance program for Leqvio
• Household income at or below 400% to 600% of the federal poverty level (thresholds adjust annually)

Applications are submitted through the prescriber's office or directly via the Novartis support portal. Processing takes 2 to 4 weeks. Patients in the application period who need a bridge may qualify for sample injections at the prescriber's discretion.

For Missouri patients who are uninsured (estimated 8.4% of the non-elderly population in Missouri as of 2024 [4]) and do not qualify for Medicaid, the PAP is frequently the most cost-effective pathway to branded Leqvio. Compounded inclisiran from a 503A pharmacy remains the other route.

What LDL Reduction Means Clinically: Putting the Cost in Context

Inclisiran's cost only makes sense alongside its clinical impact. In ORION-10 (N = 1,561, statin-treated ASCVD patients), inclisiran reduced LDL-C by 52.3% at day 510 versus a 0.5% change with placebo (P<0.001) [2]. In ORION-11 (N = 1,617, HeFH and high cardiovascular risk), LDL-C fell 49.9% versus 1.8% placebo at day 510 (P<0.001) [2].

The Cholesterol Treatment Trialists Collaboration meta-analysis of 26 randomized trials found that each 1 mmol/L (roughly 38.7 mg/dL) reduction in LDL-C reduces major vascular events by approximately 22% per year [9]. A patient starting at LDL-C 130 mg/dL who achieves 52% reduction lands near 62 mg/dL, a drop of about 68 mg/dL (1.76 mmol/L). That predicts roughly a 39% reduction in major vascular event rate per year held at that level.

For a Missouri patient who has already had one MI, the cost-per-event-prevented math may justify aggressive pursuit of insurance coverage, savings cards, or the PAP before accepting that Leqvio is unaffordable.

Step-by-Step: How a Missouri Patient Gets Leqvio in 2026

Getting inclisiran prescribed and paid for in Missouri involves more steps than most oral drugs. Here is a practical sequence for 2026:

1. Order a fasting lipid panel and confirm LDL-C level with a licensed Missouri provider (telehealth or in-person).
2. Document statin history, including current dose, duration, and any intolerance events.
3. The prescriber submits prior authorization to the commercial insurer (or, if uninsured, begins PAP enrollment).
4. Enroll in the Novartis savings card program if commercially insured.
5. Schedule the first injection at a Missouri clinic, cardiology office, or infusion center enrolled in the Leqvio buy-and-bill program.
6. Return at day 90 for the second loading dose injection.
7. Receive maintenance injections every 6 months thereafter.

If the PA is denied, the prescriber files an appeal citing ACC/AHA Class I, LOE: A guideline support [5] and attaches lab documentation. If the appeal fails and the patient cannot access the PAP, compounded inclisiran from a Missouri 503A pharmacy with a valid prescription becomes the primary remaining option.